Pharmaceutical company Alfacyte is relocating to the BioCity complex in Lanarkshire as it pursues developing of an oral vaccine to treat peanut allergy.

The company, formed in 2012, is moving from its Glasgow based just a few weeks after securing £350,000 of funding from the EOS Technology Investment Syndicate and the, Scottish Investment Bank to accelerate development of its product.

Gillian Brown, Alfacyte chief executive said: "As a very young and very small SME, we feel BioCity offers not just excellent facilities but an opportunity to mix with similar companies and share experiences.

“BioCity is more than just a location for our business, we can also benefit from the support and knowledge of its team and its network.”